Prognostic role of chemotherapy-induced neutropenia in first-line treatment of advanced ovarian cancer. A pooled analysis of MITO2 and MITO7 trials

Gennaro Daniele, Laura Arenare, Giovanni Scambia, Carmela Pisano, Roberto Sorio, Enrico Breda, Sabino De Placido, Antonella Savarese, Gabriella Ferrandina, Francesco Raspagliesi, Pierluigi Benedetti Panici, Antonella Ferro, Anita Rimanti, Gennaro Cormio, Domenica Lorusso, Sabrina Chiara Cecere, Simona Scalone, Valentina Angela Marsico, Cinzia Cardalesi, Francesco CognettiVanda Salutari, Laura Attademo, Lorenzo Guizzaro, Clorinda Schettino, Maria Carmela Piccirillo, Francesco Perrone, Ciro Gallo, Sandro Pignata

Research output: Contribution to journalArticlepeer-review

Abstract

BACKGROUND: Chemotherapy-induced neutropenia (CIN) has been associated with improved prognosis in several cancer conditions. Contrasting data have been produced in ovarian cancer.

Original languageEnglish
Pages (from-to)83-88
Number of pages6
JournalGynecologic Oncology
Volume154
Issue number1
DOIs
Publication statusPublished - Jul 2019

Keywords

  • Antineoplastic Combined Chemotherapy Protocols/adverse effects
  • Carboplatin/administration & dosage
  • Doxorubicin/administration & dosage
  • Female
  • Humans
  • Kaplan-Meier Estimate
  • Middle Aged
  • Neoplasm Staging
  • Neutropenia/chemically induced
  • Ovarian Neoplasms/blood
  • Paclitaxel/administration & dosage
  • Polyethylene Glycols/administration & dosage
  • Prognosis
  • Progression-Free Survival
  • Prospective Studies
  • Retrospective Studies

Fingerprint Dive into the research topics of 'Prognostic role of chemotherapy-induced neutropenia in first-line treatment of advanced ovarian cancer. A pooled analysis of MITO2 and MITO7 trials'. Together they form a unique fingerprint.

Cite this